Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 366789-02-8 | Product Number: R0269
Rivaroxaban
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (S)-5-Chloro-N-[[2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 1G |
€55.00
|
Contact Us | 3 |
|
| 5G |
€180.00
|
1 | 16 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | R0269 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__9H__1__8ClN__3O__5S = 435.88 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 366789-02-8 |
| Reaxys Registry Number | 10206739 |
| MDL Number | MFCD11974010 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 230.0 to 234.0 °C |
| Specific rotation | -40.0 to -44.0 deg(C=1, DMSO) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 232 °C |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Dimethylformamide |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. H371 : May cause damage to organs. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. |
Related Laws:
Transport Information:
| HS Number | 2934999090 |
Application
Rivaroxaban: A Selective Inhibitor of the Serine Protease, Activated Anticoagulant Factor X (FXa)
Rivaroxaban (BAY 59-7939) is a selective inhibitor of the serine protease, activated anticoagulant factor X (FXa) that catalyzes the conversion of prothrombin to thrombin. Rivaroxaban works by selectively and reversibly blocking the activity of clotting FXa, thereby preventing the formation of blood clots. Thus, inhibition of FXa may block this burst of thrombin generation, thereby reducing thrombin-mediated activation of coagulation and platelets. In another words, rivaroxaban does not directly affect platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. (The product is for research purpose only.)
References
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -an oral, direct factor Xa inhibitor
- Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases (a review)
- The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
- Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.